Opaque diagnostics: clouds cast shadows over sector
This article was originally published in Clinica
Executive Summary
One would have thought that the announcement of the $2.2bn acquisition of private Danish cancer diagnostics company Dako by scientific instrument maker Agilent (www.clinica.co.uk, 18 May 2012), in the same week that the forthcoming American Society for Clinical Oncology (ASCO) conference abstracts were published, would light the touch paper under the field of cancer diagnostics. However, more than one dark commercial cloud cast long shadows over the diagnostics sector.